414 related articles for article (PubMed ID: 10943745)
1. Thyroid-stimulating antibody in a patient with euthyroid Graves' disease.
Kubo T; Toki J; Kado Y; Kurihara M; Moriwake T; Kanzaki S; Seino Y
Endocr J; 2000 Apr; 47(2):197-201. PubMed ID: 10943745
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
3. Significance of thyroid stimulating antibody and long term follow up in patients with euthyroid Graves' disease.
Kashiwai T; Tada H; Asahi K; Hidaka Y; Tamaki H; Iwatani Y; Amino N
Endocr J; 1995 Jun; 42(3):405-12. PubMed ID: 7670570
[TBL] [Abstract][Full Text] [Related]
4. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
[TBL] [Abstract][Full Text] [Related]
5. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
6. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
8. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
[TBL] [Abstract][Full Text] [Related]
9. Preserved activation of thyrotropin receptor antibody to stimulate thyroid function despite long-term treatment in euthyroid patients with Graves' disease.
Akuzawa M; Murakami M; Yamada M; Satoh T; Shimizu H; Mori M
Eur J Endocrinol; 1998 Mar; 138(3):281-5. PubMed ID: 9539302
[TBL] [Abstract][Full Text] [Related]
10. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
11. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
12. Clinical features of primary hyperthyroidism caused by Graves' disease admixed with resistance to thyroid hormone (P453T).
Sato H
Endocr J; 2010; 57(8):687-92. PubMed ID: 20574139
[TBL] [Abstract][Full Text] [Related]
13. Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease.
Kawakami-Tani T; Fukawa E; Tanaka H; Abe Y; Makino I
Metabolism; 1997 Oct; 46(10):1184-8. PubMed ID: 9322804
[TBL] [Abstract][Full Text] [Related]
14. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
16. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
Buerklin EM; Schimmel M; Utiger RD
J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
[TBL] [Abstract][Full Text] [Related]
17. Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients.
Brokken LJ; Wiersinga WM; Prummel MF
J Clin Endocrinol Metab; 2003 Sep; 88(9):4135-8. PubMed ID: 12970276
[TBL] [Abstract][Full Text] [Related]
18. A case of pulmonary metastatic thyroid cancer complicated with Graves' disease.
Suzuki K; Nakagawa O; Aizawa Y
Endocr J; 2001 Apr; 48(2):175-9. PubMed ID: 11456264
[TBL] [Abstract][Full Text] [Related]
19. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
Chen W; Man N; Li YS; Shan ZY; Teng WP
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
[TBL] [Abstract][Full Text] [Related]
20. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
